Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | BMEA |
---|---|---|
09:32 ET | 8891 | 5.34 |
09:34 ET | 8295 | 5.33 |
09:36 ET | 5103 | 5.37 |
09:38 ET | 889 | 5.3498 |
09:39 ET | 3305 | 5.37 |
09:41 ET | 1098 | 5.39 |
09:43 ET | 2357 | 5.38 |
09:45 ET | 1100 | 5.33 |
09:48 ET | 729 | 5.38 |
09:50 ET | 789 | 5.38 |
09:52 ET | 500 | 5.38 |
09:54 ET | 3873 | 5.43 |
09:56 ET | 12991 | 5.475 |
09:57 ET | 8685 | 5.45 |
09:59 ET | 908 | 5.4501 |
10:01 ET | 2590 | 5.45 |
10:03 ET | 1135 | 5.39 |
10:06 ET | 14925 | 5.35 |
10:08 ET | 1949 | 5.35 |
10:10 ET | 1200 | 5.335 |
10:12 ET | 1800 | 5.315 |
10:14 ET | 3239 | 5.25 |
10:15 ET | 4591 | 5.29 |
10:17 ET | 1165 | 5.27 |
10:19 ET | 500 | 5.27 |
10:21 ET | 1500 | 5.27 |
10:24 ET | 3356 | 5.3 |
10:26 ET | 1847 | 5.28 |
10:28 ET | 1300 | 5.265 |
10:30 ET | 4186 | 5.26 |
10:32 ET | 925 | 5.26 |
10:33 ET | 7439 | 5.3 |
10:35 ET | 1554 | 5.3 |
10:37 ET | 400 | 5.285 |
10:39 ET | 983 | 5.29 |
10:42 ET | 700 | 5.27 |
10:44 ET | 700 | 5.265 |
10:46 ET | 700 | 5.26 |
10:48 ET | 6900 | 5.252 |
10:50 ET | 1888 | 5.26 |
10:51 ET | 2100 | 5.26 |
10:53 ET | 1358 | 5.26 |
10:55 ET | 1906 | 5.27 |
10:57 ET | 1050 | 5.2516 |
11:00 ET | 500 | 5.25 |
11:02 ET | 400 | 5.25 |
11:04 ET | 3259 | 5.2501 |
11:06 ET | 700 | 5.26 |
11:08 ET | 1461 | 5.27 |
11:09 ET | 1578 | 5.29 |
11:11 ET | 1640 | 5.3 |
11:13 ET | 2177 | 5.3021 |
11:15 ET | 489 | 5.33 |
11:18 ET | 1100 | 5.31 |
11:20 ET | 500 | 5.28 |
11:22 ET | 1886 | 5.32 |
11:24 ET | 600 | 5.325 |
11:26 ET | 2078 | 5.34 |
11:27 ET | 600 | 5.32 |
11:29 ET | 400 | 5.32 |
11:31 ET | 600 | 5.3 |
11:33 ET | 300 | 5.3 |
11:36 ET | 500 | 5.27 |
11:38 ET | 700 | 5.27 |
11:40 ET | 1000 | 5.2766 |
11:42 ET | 4259 | 5.29 |
11:44 ET | 2641 | 5.31 |
11:45 ET | 4482 | 5.31 |
11:47 ET | 400 | 5.3 |
11:49 ET | 927 | 5.34 |
11:51 ET | 964 | 5.37 |
11:54 ET | 300 | 5.37 |
11:56 ET | 3288 | 5.385 |
11:58 ET | 100 | 5.385 |
12:00 ET | 200 | 5.38 |
12:02 ET | 851 | 5.39 |
12:03 ET | 4106 | 5.42 |
12:05 ET | 1205 | 5.39 |
12:07 ET | 400 | 5.39 |
12:09 ET | 200 | 5.39 |
12:12 ET | 1595 | 5.38 |
12:14 ET | 2310 | 5.36 |
12:16 ET | 7733 | 5.36 |
12:18 ET | 545 | 5.37 |
12:20 ET | 27486 | 5.38 |
12:21 ET | 500 | 5.37 |
12:23 ET | 384 | 5.3762 |
12:25 ET | 10843 | 5.375 |
12:27 ET | 300 | 5.375 |
12:30 ET | 500 | 5.355 |
12:32 ET | 1700 | 5.3 |
12:34 ET | 429 | 5.3 |
12:36 ET | 1500 | 5.29 |
12:38 ET | 400 | 5.29 |
12:39 ET | 8289 | 5.3 |
12:41 ET | 800 | 5.32 |
12:43 ET | 821 | 5.32 |
12:45 ET | 300 | 5.32 |
12:48 ET | 200 | 5.32 |
12:50 ET | 300 | 5.32 |
12:52 ET | 550 | 5.31 |
12:54 ET | 100 | 5.3 |
12:56 ET | 800 | 5.31 |
12:57 ET | 196 | 5.31 |
12:59 ET | 300 | 5.31 |
01:01 ET | 2938 | 5.29 |
01:03 ET | 480 | 5.3 |
01:06 ET | 300 | 5.3 |
01:08 ET | 300 | 5.31 |
01:10 ET | 1522 | 5.3 |
01:12 ET | 1032 | 5.3 |
01:14 ET | 300 | 5.31 |
01:15 ET | 850 | 5.31 |
01:17 ET | 300 | 5.31 |
01:19 ET | 4567 | 5.29 |
01:21 ET | 3000 | 5.29 |
01:24 ET | 781 | 5.3 |
01:26 ET | 400 | 5.29 |
01:28 ET | 10077 | 5.26 |
01:30 ET | 3500 | 5.23 |
01:32 ET | 200 | 5.26 |
01:33 ET | 4245 | 5.2301 |
01:35 ET | 5140 | 5.25 |
01:37 ET | 700 | 5.26 |
01:39 ET | 1100 | 5.24 |
01:42 ET | 3208 | 5.23 |
01:44 ET | 200 | 5.24 |
01:46 ET | 200 | 5.25 |
01:48 ET | 900 | 5.26 |
01:50 ET | 922 | 5.27 |
01:51 ET | 500 | 5.27 |
01:53 ET | 500 | 5.27 |
01:55 ET | 2474 | 5.29 |
01:57 ET | 5200 | 5.3 |
02:00 ET | 2337 | 5.31 |
02:02 ET | 300 | 5.32 |
02:04 ET | 1092 | 5.34 |
02:06 ET | 300 | 5.34 |
02:08 ET | 300 | 5.34 |
02:09 ET | 1200 | 5.3127 |
02:11 ET | 811 | 5.34 |
02:13 ET | 400 | 5.34 |
02:15 ET | 1902 | 5.36 |
02:18 ET | 400 | 5.37 |
02:20 ET | 300 | 5.37 |
02:22 ET | 500 | 5.37 |
02:24 ET | 1902 | 5.37 |
02:26 ET | 3971 | 5.4 |
02:27 ET | 442 | 5.4 |
02:29 ET | 11182 | 5.41 |
02:31 ET | 1906 | 5.43 |
02:33 ET | 200 | 5.44 |
02:36 ET | 600 | 5.43 |
02:38 ET | 31331 | 5.36 |
02:40 ET | 1093 | 5.365 |
02:42 ET | 900 | 5.36 |
02:44 ET | 8930 | 5.345 |
02:45 ET | 500 | 5.36 |
02:47 ET | 3205 | 5.34 |
02:49 ET | 600 | 5.345 |
02:51 ET | 325 | 5.345 |
02:54 ET | 1788 | 5.33 |
02:56 ET | 1371 | 5.34 |
02:58 ET | 200 | 5.34 |
03:00 ET | 1600 | 5.34 |
03:02 ET | 3100 | 5.34 |
03:03 ET | 300 | 5.34 |
03:05 ET | 3254 | 5.33 |
03:07 ET | 2824 | 5.3293 |
03:09 ET | 628 | 5.32 |
03:12 ET | 1774 | 5.31 |
03:14 ET | 1280 | 5.33 |
03:16 ET | 1941 | 5.34 |
03:18 ET | 900 | 5.338 |
03:20 ET | 2360 | 5.36 |
03:21 ET | 710 | 5.39 |
03:23 ET | 1882 | 5.39 |
03:25 ET | 1900 | 5.41 |
03:27 ET | 1589 | 5.39 |
03:30 ET | 1530 | 5.3972 |
03:32 ET | 900 | 5.39 |
03:34 ET | 1390 | 5.38 |
03:36 ET | 3700 | 5.39 |
03:38 ET | 4015 | 5.42 |
03:39 ET | 3880 | 5.4223 |
03:41 ET | 3300 | 5.42 |
03:43 ET | 500 | 5.42 |
03:45 ET | 2378 | 5.41 |
03:48 ET | 1600 | 5.4 |
03:50 ET | 1500 | 5.395 |
03:52 ET | 1180 | 5.39 |
03:54 ET | 7373 | 5.385 |
03:56 ET | 6397 | 5.395 |
03:57 ET | 14876 | 5.365 |
03:59 ET | 53220 | 5.36 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Biomea Fusion Inc | 192.7M | -1.5x | --- |
XBiotech Inc | 191.6M | -6.2x | --- |
Pyxis Oncology Inc | 188.4M | -2.3x | --- |
Candel Therapeutics Inc | 197.0M | -5.1x | --- |
Outlook Therapeutics Inc | 197.8M | -0.7x | --- |
INmune Bio Inc | 188.5M | -5.0x | --- |
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $192.7M |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 35.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-3.57 |
Book Value | $4.72 |
P/E Ratio | -1.5x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.